Rising costs of innovative medicines are creating major affordability and access challenges worldwide, particularly in the United States where drug prices remain significantly higher than in other high-income nations. While these therapies—especially in areas like oncology, rare diseases, and gene treatments—offer significant clinical benefits, they are placing increasing financial pressure on public programs, insurers, and patients, often worsening health inequities.
An international review of pricing and financing strategies across countries including Australia, Canada, England, France, Germany, and Sweden highlights several policy approaches that could inform U.S. reforms. These countries, all operating under universal health coverage systems, have developed coordinated frameworks to balance access to new treatments with financial sustainability.
A central lesson is the importance of health technology assessment (HTA), a structured process used to evaluate the clinical effectiveness and value of new medicines. Countries such as England rely on institutions like National Institute for Health and Care Excellence, while Germany uses the AMNOG system to link pricing decisions to demonstrated clinical benefit. These frameworks help ensure transparency and consistency in determining which medicines should be publicly funded.
Another key strategy is centralized or collaborative price negotiation. National systems in France and Germany negotiate directly with manufacturers, while Canada uses joint provincial negotiations through the pan-Canadian Pharmaceutical Alliance. Even in decentralized systems, coordination improves bargaining power and helps secure more predictable pricing. In contrast, the fragmented U.S. healthcare system limits such unified negotiation, though some initiatives like Medicare drug price negotiations show emerging progress.
Countries also use structured access pathways, such as managed entry agreements, to allow early access to high-cost medicines while collecting additional data on their effectiveness. Programs like England’s Cancer Drugs Fund provide temporary coverage for promising therapies while evidence is gathered. Although outcome-based payment models remain limited due to data and administrative challenges, financial agreements such as rebates and price caps are widely used to manage costs and uncertainty.
A critical enabler of these approaches is strong data infrastructure. Countries with advanced health data systems, such as Sweden, are better positioned to track patient outcomes and support value-based pricing. In the U.S., fragmented data systems and lack of standardized outcome tracking remain major barriers to implementing such models effectively, highlighting the need for investment in interoperable data systems and real-world evidence capabilities.
Equity and patient protection are also central to international approaches. In the countries studied, patients typically face low or capped out-of-pocket costs for covered medicines, with high-cost treatments financed through pooled or national funding mechanisms. This contrasts with the U.S., where patients often bear significant financial burdens, underscoring the need for stronger affordability safeguards.
Overall, the international experience demonstrates that improving access to high-cost medicines requires coordinated policy design that combines evidence-based decision-making, stronger negotiation mechanisms, flexible financing tools, and explicit equity protections. While adapting these models to the U.S. will be challenging due to system fragmentation and regulatory constraints, targeted reforms—such as multipayer collaboration, investment in data infrastructure, and phased policy implementation—could help create a more sustainable and equitable system for accessing life-saving therapies.
